ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Intra-Cellular Therapies (ITCI) reported fourth-quarter 2024 loss of 16 cents per share, wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had incurred a loss of 29 cents per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Total revenues, comprising only net product sales, came in at $199.2 million, up 51% year over year on the back of strong prescription uptake. The top line beat the Zacks Consensus Estimate of $193 million.ITCI’s ...